These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4081643)

  • 1. Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis.
    de Pauw BE; van Bergen AN; Haanen C; Steenbergen J
    Scand J Haematol; 1985 Oct; 35(4):448-50. PubMed ID: 4081643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorrhagic thrombocythemia; control of postsplenectomy thrombocytosis with melphalan.
    Bensinger TA; Logue GL; Rundles RW
    Blood; 1970 Jul; 36(1):61-9. PubMed ID: 5463461
    [No Abstract]   [Full Text] [Related]  

  • 3. [Primary thrombocythemia in childhood].
    Flapper B; Van Oostrom C; de Vaan G
    Tijdschr Kindergeneeskd; 1983 Jun; 51(3):77-85. PubMed ID: 6685355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
    Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
    Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic thrombocythemia and pregnancy; a case report.
    Minkhorst AG; Nováková IR; van Dongen PW
    Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):237-8. PubMed ID: 1879600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
    Penka M; Schwarz J; Pavlík T; Indrák K; Doubek M; Dulícek P; Pospísilová D; Kissová J; Jonásová A; Jelínková P; Hlusí A; Schutzová M; Cerná O; Brychtová Y; Nováková L; Korístek Z; Segethová J; Vozobulová V; Hadacová I; Hochová I; Voglová J; Walterová L; Bodzásová C; Dusek L
    Vnitr Lek; 2009 Nov; 55(11):I-XII. PubMed ID: 20017445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
    Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
    Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytosis and thrombocythemia.
    Schafer AI
    Blood Rev; 2001 Dec; 15(4):159-66. PubMed ID: 11792116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
    Dingli D; Tefferi A
    Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis.
    Törnebohm-Roche E; Merup M; Lockner D; Paul C
    Am J Hematol; 1995 Mar; 48(3):163-7. PubMed ID: 7864024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary artery bypass grafting for left main trunk coronary artery lesion associated with essential thrombocythemia.
    Momiyama T; Hiranaka T; Nomura F; Tominaga H; Nishioka T
    Clin Cardiol; 1993 Sep; 16(9):691-3. PubMed ID: 8242914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
    Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
    Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of adults presenting with a thrombocytosis].
    Viallard JF
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S333-8. PubMed ID: 21035235
    [No Abstract]   [Full Text] [Related]  

  • 16. [Long-term treatment of thrombocytosis and thrombocythemia].
    Linker H; Lindner HJ; Reuter H; Gross R
    Med Welt; 1980 Apr; 31(14):509-12. PubMed ID: 7189572
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of essential thrombocythemia].
    Kuramoto A
    Rinsho Ketsueki; 1995 May; 36(5):480-6. PubMed ID: 7783354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
    Murphy S; Rosenthal DS; Weinfeld A; Briere J; Faguet GB; Knospe WH; Landaw SA; Laszlo J; Pisciotta AV; Tartaglia AP
    Cancer Treat Rep; 1982 Jul; 66(7):1495-500. PubMed ID: 7046930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis].
    Yao HX; Huang L; Wu CM; Lin LE; Huang ZQ; Wu JF; Wang SW; Chen WT; Tang RM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1360-2. PubMed ID: 19840484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.